Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

被引：0
|
作者：
Shizuko Sei
Jodie K Mussio
Quan-en Yang
Kunio Nagashima
Ralph E Parchment
Matthew C Coffey
Robert H Shoemaker
Joseph E Tomaszewski
机构：
[1] SAIC-Frederick,Laboratory of Human Toxicology and Pharmacology
[2] Inc,Electron Microscope Laboratory
[3] NCI-Frederick,Developmental Therapeutics Program
[4] SAIC-Frederick,Division of Cancer Treatment and Diagnostics
[5] Inc,undefined
[6] NCI-Frederick,undefined
[7] Oncolytics Biotech Inc,undefined
[8] National Cancer Institute,undefined
[9] National Cancer Institute,undefined
来源：
Molecular Cancer | / 8卷
关键词：
Paclitaxel; Gemcitabine; NSCLC Cell; Combination Index; NSCLC Cell Line;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Antitumor activity of noscapine in human non-small cell lung cancer xenograft model
    Tanise Jackson
    Mahavir B. Chougule
    Nkechi Ichite
    Ram R. Patlolla
    Mandip Singh
    Cancer Chemotherapy and Pharmacology, 2008, 63 : 117 - 126
  • [22] Antitumor activity of noscapine in human non-small cell lung cancer xenograft model
    Jackson, Tanise
    Chougule, Mahavir B.
    Ichite, Nkechi
    Patlolla, Ram R.
    Singh, Mandip
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 63 (01) : 117 - 126
  • [23] ANTITUMOR ACTIVITY OF CURCUMIN IN A HUMAN NON-SMALL CELL LUNG CANCER XENOGRAFT MODEL
    Su, Chin-Cheng
    Chen, Guang-Wei
    Yang, Jai-Sing
    Wu, Chang-Lin
    Lu, Chi-Cheng
    Chung, Jing-Gung
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3501 - 3501
  • [24] Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer
    Nakamura, Yoichi
    Sano, Kazumi
    Soda, Hiroshi
    Takatani, Hiroshi
    Fukuda, Minoru
    Nagashima, Seiji
    Hayashi, Tomayoshi
    Oka, Mikio
    Tsukamoto, Kazuhiro
    Kohno, Shigeru
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (09) : 1404 - 1409
  • [25] Apatinib to enhance antitumor activity of gefitinib in non-small cell lung cancer.
    Li, Fang
    Zhu, Tengjiao
    Zhu, Xiang
    Wang, Jiadong
    Liang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer
    Yu, J. L.
    Simmons, C. E.
    Victor, C.
    Han, D.
    Hogeveen, S.
    Leighl, N. B.
    Verma, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Impact of New Chemotherapeutic and Targeted Agents on Survival in Stage IV Non-Small Cell Lung Cancer
    Yu, Joanne L.
    Simmons, Christine
    Victor, J. Charles
    Han, Dolly
    Hogeveen, Sophie
    Leighl, Natasha
    Verma, Sunil
    ONCOLOGIST, 2011, 16 (09): : 1307 - 1315
  • [28] Combination of MAPK inhibitor CI-1040 and conventional chemotherapeutic agents has synergistic effect in non-small cell lung cancer cell lines
    Molina, A
    Vicent, S
    Collantes, M
    Montuenga, L
    LUNG CANCER, 2005, 49 : S374 - S374
  • [29] Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer
    Subhani, Syed
    Jamil, Kaiser
    BIOMEDICINE & PHARMACOTHERAPY, 2015, 73 : 65 - 74
  • [30] Chemotherapeutic management of stage IV non-small cell lung cancer
    Socinski, MA
    Morris, DE
    Masters, GA
    Lilenbaum, R
    CHEST, 2003, 123 (01) : 226S - 243S
12345